{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:02:37Z","timestamp":1787752957466,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04854-9","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:08:30Z","timestamp":1772096910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concurrence of renal amyloidosis and membranous nephropathy: a case series and literature review"],"prefix":"10.1186","volume":"27","author":[{"given":"Ling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"4854_CR1","doi-asserted-by":"publisher","first-page":"108122","DOI":"10.1016\/j.pharmthera.2022.108122","volume":"235","author":"Y Cho","year":"2022","unstructured":"Cho Y, et al. Physiology and pharmacology of amyloid precursor protein. Pharmacol Ther. 2022;235:108122.","journal-title":"Pharmacol Ther"},{"key":"4854_CR2","doi-asserted-by":"crossref","unstructured":"Leung N, Nasr SH. 2024 update on classification, etiology, and typing of renal amyloidosis: a review. Am J Kidney Dis; 2024.","DOI":"10.1053\/j.ajkd.2024.01.530"},{"issue":"6","key":"4854_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ckj\/sfv087","volume":"8","author":"MM Picken","year":"2015","unstructured":"Picken MM. Proteomics and mass spectrometry in the diagnosis of renal amyloidosis. Clin Kidney J. 2015;8(6):665\u201372.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4854_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000444287","volume":"2","author":"XH Huang","year":"2016","unstructured":"Huang XH, Liu ZH. The clinical presentation and management of systemic light-chain amyloidosis in China. Kidney Dis (Basel). 2016;2(1):1\u20139.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"4854_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2020.03.030","volume":"98","author":"O Gursky","year":"2020","unstructured":"Gursky O. Novel clinical manifestations and treatment of hereditary apoA-I amyloidosis: when a good protein turns bad. Kidney Int. 2020;98(1):62\u20134.","journal-title":"Kidney Int"},{"key":"4854_CR6","doi-asserted-by":"publisher","first-page":"e12284","DOI":"10.1590\/1414-431x2022e12284","volume":"55","author":"VA Feitosa","year":"2022","unstructured":"Feitosa VA, et al. Renal amyloidosis: a new time for a complete diagnosis. Braz J Med Biol Res. 2022;55:e12284.","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"4854_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/13506129.2022.2070741","volume":"29","author":"OC Cohen","year":"2022","unstructured":"Cohen OC, Blakeney IJ, Law S, et al. The experience of hereditary apolipoprotein A-I amyloidosis at the UK national amyloidosis centre. Amyloid. 2022;29(4):237\u201344.","journal-title":"Amyloid"},{"issue":"9","key":"4854_CR8","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403\u201312.","journal-title":"Hum Mutat"},{"issue":"1","key":"4854_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","volume":"56","author":"RJ Glassock","year":"2010","unstructured":"Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56(1):157\u201367.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4854_CR10","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1053\/j.ajkd.2015.07.006","volume":"66","author":"AB Fogo","year":"2015","unstructured":"Fogo AB, et al. AJKD atlas of renal pathology: membranous nephropathy. Am J Kidney Dis. 2015;66(3):e15\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4854_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LJ Beck","year":"2009","unstructured":"Beck LJ, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"4854_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/ki.2013.558","volume":"86","author":"SM Said","year":"2014","unstructured":"Said SM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014;86(2):370\u20137.","journal-title":"Kidney Int"},{"key":"4854_CR13","doi-asserted-by":"publisher","first-page":"876512","DOI":"10.3389\/fphar.2022.876512","volume":"13","author":"W Qu","year":"2022","unstructured":"Qu W, et al. Case report: coexistence of anti-glomerular basement membrane disease, membranous nephropathy, and IgA nephropathy in a female patient with preserved renal function. Front Pharmacol. 2022;13:876512.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4854_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12882-023-03268-1","volume":"24","author":"T Yamazaki","year":"2023","unstructured":"Yamazaki T, et al. Rare case of exostosin 1\/exostosin 2-related membranous lupus nephritis concomitant with dual ANCA- and anti-GBM antibody-associated crescentic glomerulonephritis effectively diagnosed by mass spectrometry: a case report. BMC Nephrol. 2023;24(1):218.","journal-title":"BMC Nephrol"},{"issue":"4","key":"4854_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF00465597","volume":"378","author":"A Bohle","year":"1978","unstructured":"Bohle A, et al. Simultaneous occurrence of perimembranous glomerulonephritis and glomerular amyloidosis. Virchows Arch Pathol Anat Histol. 1978;378(4):315\u201320.","journal-title":"Virchows Arch Pathol Anat Histol"},{"key":"4854_CR16","doi-asserted-by":"crossref","unstructured":"Kapp M, Sodeinde A, Jittirat A. WCN23-1132 A limited biopsy reveals an uncommon combination: membranous nephropathy and AA amyloidosis. Kidney Int Rep. 2023;8(3 Suppl):S261\u20132.","DOI":"10.1016\/j.ekir.2023.02.592"},{"issue":"1","key":"4854_CR17","doi-asserted-by":"publisher","first-page":"2486562","DOI":"10.1080\/0886022X.2025.2486562","volume":"47","author":"Z Li","year":"2025","unstructured":"Li Z, Liu J, Zhu S, et al. Membranous nephropathy concurrent with renal amyloidosis: a six-patient report and literature review. Ren Fail. 2025;47(1):2486562.","journal-title":"Ren Fail"},{"issue":"39","key":"4854_CR18","doi-asserted-by":"publisher","first-page":"e8148","DOI":"10.1097\/MD.0000000000008148","volume":"96","author":"C Lu","year":"2017","unstructured":"Lu C, et al. Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature. Med (Baltim). 2017;96(39):e8148.","journal-title":"Med (Baltim)"},{"issue":"13","key":"4854_CR19","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1111\/jcmm.17407","volume":"26","author":"Y Xie","year":"2022","unstructured":"Xie Y, et al. LECT2: a pleiotropic and promising hepatokine, from bench to bedside. J Cell Mol Med. 2022;26(13):3598\u2013607.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"4854_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/ki.2008.152","volume":"74","author":"MD Benson","year":"2008","unstructured":"Benson MD, et al. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int. 2008;74(2):218\u201322.","journal-title":"Kidney Int"},{"issue":"2","key":"4854_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/ndt\/gfw375","volume":"33","author":"T Rezk","year":"2018","unstructured":"Rezk T, et al. Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrol Dial Transpl. 2018;33(2):241\u20137.","journal-title":"Nephrol Dial Transpl"},{"issue":"39","key":"4854_CR22","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","volume":"43","author":"S Halvorsen","year":"2022","unstructured":"Halvorsen S, et al. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J. 2022;43(39):3826\u2013924.","journal-title":"Eur Heart J"},{"issue":"6","key":"4854_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller C, McDonald K, de Boer RA, et al. Heart failure association of the european society of cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715\u201331.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"4854_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4049\/jimmunol.173.1.579","volume":"173","author":"T Saito","year":"2004","unstructured":"Saito T, et al. Increase in hepatic NKT cells in leukocyte cell-derived chemotaxin 2-deficient mice contributes to severe concanavalin A-induced hepatitis. J Immunol. 2004;173(1):579\u201385.","journal-title":"J Immunol"},{"issue":"7","key":"4854_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","volume":"364","author":"HC Stanescu","year":"2011","unstructured":"Stanescu HC, et al. Risk HLA-DQA1 and PLA2 R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364(7):616\u201326.","journal-title":"N Engl J Med"},{"issue":"23","key":"4854_CR26","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.12998\/wjcc.v11.i23.5538","volume":"11","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang X, Zou GM, Li JY, Li WG. Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: a case report. World J Clin Cases. 2023;11(23):5538\u201346.","journal-title":"World J Clin Cases"},{"key":"4854_CR27","doi-asserted-by":"publisher","first-page":"986065","DOI":"10.3389\/fmed.2022.986065","volume":"9","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Idiopathic membranous nephropathy with renal amyloidosis: a case report. Front Med (Lausanne). 2022;9:986065.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"4854_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pathol.2021.08.008","volume":"54","author":"A Morel","year":"2022","unstructured":"Morel A, et al. Thrombospondin type-1 domain-containing 7A-related membranous nephropathy associated with glomerular AL amyloidosis. Pathology. 2022;54(5):654\u20137.","journal-title":"Pathology"},{"issue":"1","key":"4854_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12882-023-03331-x","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, et al. First case report of PLA2R-related monotypic (IgG-kappa positive) membranous nephropathy concurrent with leukocyte chemotactic factor 2 amyloidosis. BMC Nephrol. 2023;24(1):283.","journal-title":"BMC Nephrol"},{"issue":"6","key":"4854_CR30","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/ckj\/sfab269","volume":"15","author":"M Li","year":"2021","unstructured":"Li M, Xu G. An update of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Clin Kidney J. 2021;15(6):1041\u20138. Published 2021 Dec 14.","journal-title":"Clin Kidney J"},{"key":"4854_CR31","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2009010110","volume":"20","author":"SH Nasr","year":"2009","unstructured":"Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"4854_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1523-1755.2004.00365.x","volume":"65","author":"SH Nasr","year":"2004","unstructured":"Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int. 2004;65:85\u201396.","journal-title":"Kidney Int"},{"issue":"2","key":"4854_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.kint.2025.04.007","volume":"108","author":"SH Nasr","year":"2025","unstructured":"Nasr SH, Royal V, Best Rocha A, et al. Renal pathology society\/international Kidney and monoclonal gammopathy research group consensus on pathologic definitions and terminology of monoclonal gammopathy-associated kidney lesions. Kidney Int. 2025;108(2):184\u201393. https:\/\/doi.org\/10.1016\/j.kint.2025.04.007.","journal-title":"Kidney Int"},{"issue":"2","key":"4854_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ckj\/sfu021","volume":"7","author":"MA Khalighi","year":"2014","unstructured":"Khalighi MA, Dean WW. Palma-Diaz, Amyloid nephropathy. Clin Kidney J. 2014;7(2):97\u2013106.","journal-title":"Clin Kidney J"},{"issue":"1","key":"4854_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1681\/ASN.0000000000000221","volume":"35","author":"S Sethi","year":"2023","unstructured":"Sethi S, et al. From patterns to proteins: mass spectrometry comes of age in glomerular disease. J Am Soc Nephrol. 2023;35(1):117\u201328.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"4854_CR36","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106\u201314.","journal-title":"N Engl J Med"},{"issue":"10","key":"4854_CR37","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/j.1600-6143.2006.01507.x","volume":"6","author":"JD Gillmore","year":"2006","unstructured":"Gillmore JD, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transpl. 2006;6(10):2342\u20137.","journal-title":"Am J Transpl"},{"issue":"4","key":"4854_CR38","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1097\/HS9.0000000000000454","volume":"4","author":"D Fotiou","year":"2020","unstructured":"Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: current approaches to diagnosis and management. Hemasphere. 2020;4(4):e454.","journal-title":"Hemasphere"},{"issue":"15","key":"4854_CR39","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111\u20139.","journal-title":"Blood"},{"issue":"2","key":"4854_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","volume":"57","author":"C Shimazaki","year":"2018","unstructured":"Shimazaki C, et al. Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan. Intern Med. 2018;57(2):181\u20137.","journal-title":"Intern Med"},{"issue":"9","key":"4854_CR41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ajh.25149","volume":"93","author":"MA Gertz","year":"2018","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol. 2018;93(9):1169\u201380.","journal-title":"Am J Hematol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04854-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04854-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04854-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:21:38Z","timestamp":1775035298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04854-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4854"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04854-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has given written informed consent for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}